Efavirenz 400mg

DRUG3 trials

Sponsors

Kirby Institute, Shanghai Public Health Clinical Center, Peking Union Medical College Hospital

Conditions

HIV InfectionsHIV-1-infectionTuberculosis

Phase 3

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

CompletedNCT01011413

Kirby InstituteHIV Infections

Start: 2011-08-31End: 2014-08-31Updated: 2020-02-21

Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients

Shanghai Public Health Clinical CenterHIV Infections, Tuberculosis

Start: 2020-11-01End: 2023-01-31Target: 80Updated: 2020-08-14

Unknown Phase

Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients

CompletedNCT04596488

Peking Union Medical College HospitalHIV-1-infection

Start: 2017-06-01End: 2019-12-30Updated: 2020-10-23

Related Papers

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.

2021-01-2310 citations

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

2015-04-1281 citations

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Clinical Infectious Diseases2014-12-1129 citations

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

2014-02-10116 citations